Healthcare / BiotechnologyNasdaqGM
$2.95
-0.12 (-3.75%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-4.1M · quality 64.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$209M
P/E
N/A
•EV/EBITDA
N/A
•ROE
291.0%
↑Gross Margin
28.1%
↓Debt/Equity
-0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+30.6%
FCF CAGR
—
FCF margin
-1346.6%
FCF / Net income
0.97x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $596817.0 · net income $-8.3M · FCF $-8.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $596817.00 | $596817.00 | $510360.00 | $350131.00 |
| Net Income | $-8.3M | $-8.3M | $-1.4M | $13560.00 |
| EBITDA | $-8.1M | $-8.1M | $-1.3M | $22246.00 |
| EPS | — | — | — | 0.00 |
| Gross Margin | 28.1% | 28.1% | 30.4% | 43.8% |
| Operating Margin | -882.7% | -882.7% | -286.5% | -2.0% |
| Net Margin | -1392.6% | -1392.6% | -276.6% | 3.9% |
| Balance Sheet | ||||
| Debt/Equity | -0.00 | -0.00 | 0.00 | 2.07 |
| Current Ratio | 13.18 | 13.18 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-8.0M | $-8.0M | $-4.1M | $-55947.00 |
| Returns | ||||
| ROE | 291.0% | 291.0% | -21.4% | 59.0% |
| Growth & Yield | ||||
| Revenue Growth | 16.9% | 16.9% | 45.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-77.9%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
-77.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.